Xylazine's k-opioid agonist activity is not shared with other FDA-approved alpha2-adrenergic agonists
While xylazine exhibits unique kappa opioid agonist activity among FDA-approved alpha2-adrenergic agonists, a comprehensive profiling study reveals that other drugs in this class possess distinct, non-overlapping off-target GPCR activity and signaling bias profiles that may explain their specific therapeutic and adverse effects.